Published in Oncogene on December 17, 2007
Genomic instability--an evolving hallmark of cancer. Nat Rev Mol Cell Biol (2010) 7.11
Nucleotide deficiency promotes genomic instability in early stages of cancer development. Cell (2011) 4.83
Cell-type-specific replication initiation programs set fragility of the FRA3B fragile site. Nature (2011) 2.69
Global organization of replication time zones of the mouse genome. Genome Res (2008) 2.11
Telomere dysfunction and chromosome instability. Mutat Res (2011) 1.51
Replication stress and cancer. Nat Rev Cancer (2015) 1.43
A genome-wide analysis of common fragile sites: what features determine chromosomal instability in the human genome? Genome Res (2012) 1.37
Initiation of genome instability and preneoplastic processes through loss of Fhit expression. PLoS Genet (2012) 1.27
Telomere loss as a mechanism for chromosome instability in human cancer. Cancer Res (2010) 1.24
DNA damage response to the Mdm2 inhibitor nutlin-3. Biochem Pharmacol (2010) 1.17
Genome-wide profiles of H2AX and γ-H2AX differentiate endogenous and exogenous DNA damage hotspots in human cells. Nucleic Acids Res (2012) 1.16
The ATM signaling network in development and disease. Front Genet (2013) 1.09
Rev3, the catalytic subunit of Polζ, is required for maintaining fragile site stability in human cells. Nucleic Acids Res (2013) 1.08
WWOX, the common fragile site FRA16D gene product, regulates ATM activation and the DNA damage response. Proc Natl Acad Sci U S A (2014) 1.03
The contribution of dormant origins to genome stability: from cell biology to human genetics. DNA Repair (Amst) (2014) 1.01
Aberrant expression of DNA damage response proteins is associated with breast cancer subtype and clinical features. Breast Cancer Res Treat (2010) 1.01
The replicometer is broken: telomeres activate cellular senescence in response to genotoxic stresses. Aging Cell (2014) 1.00
PTEN C-terminal deletion causes genomic instability and tumor development. Cell Rep (2014) 0.98
Ataxia-telangiectasia: future prospects. Appl Clin Genet (2014) 0.94
Stress-induced DNA damage biomarkers: applications and limitations. Front Chem (2015) 0.94
Subtelomeric regions in mammalian cells are deficient in DNA double-strand break repair. DNA Repair (Amst) (2011) 0.92
The ubiquitin-proteasome system in cancer, a major player in DNA repair. Part 1: post-translational regulation. J Cell Mol Med (2009) 0.90
Are common fragile sites merely structural domains or highly organized "functional" units susceptible to oncogenic stress? Cell Mol Life Sci (2014) 0.90
Updating the mechanisms of common fragile site instability: how to reconcile the different views? Cell Mol Life Sci (2014) 0.90
A TRF1-controlled common fragile site containing interstitial telomeric sequences. Chromosoma (2012) 0.89
Lac operator repeats generate a traceable fragile site in mammalian cells. EMBO Rep (2011) 0.89
Oncogenes create a unique landscape of fragile sites. Nat Commun (2015) 0.87
Early replication fragile sites: where replication-transcription collisions cause genetic instability. EMBO J (2013) 0.87
Mechanisms of telomere loss and their consequences for chromosome instability. Front Oncol (2012) 0.87
Common fragile sites: genomic hotspots of DNA damage and carcinogenesis. Int J Mol Sci (2012) 0.87
Role of DNA secondary structures in fragile site breakage along human chromosome 10. Hum Mol Genet (2013) 0.85
High level of chromosomal aberration in ovarian cancer genome correlates with poor clinical outcome. Gynecol Oncol (2012) 0.84
Urothelial tumor initiation requires deregulation of multiple signaling pathways: implications in target-based therapies. Carcinogenesis (2012) 0.84
WWOX: a fragile tumor suppressor. Exp Biol Med (Maywood) (2014) 0.84
Genome stability control by checkpoint regulation of tRNA gene transcription. Transcription (2010) 0.83
Folate levels modulate oncogene-induced replication stress and tumorigenicity. EMBO Mol Med (2015) 0.82
Excessive MET signaling causes acquired resistance and addiction to MET inhibitors in the MKN45 gastric cancer cell line. Invest New Drugs (2013) 0.81
Alternative lengthening of telomeres: recurrent cytogenetic aberrations and chromosome stability under extreme telomere dysfunction. Neoplasia (2013) 0.81
Fragile site instability in Saccharomyces cerevisiae causes loss of heterozygosity by mitotic crossovers and break-induced replication. PLoS Genet (2013) 0.80
Genomic rearrangements at the FRA2H common fragile site frequently involve non-homologous recombination events across LTR and L1(LINE) repeats. Hum Genet (2012) 0.80
A high resolution map of mammalian X chromosome fragile regions assessed by large-scale comparative genomics. Mamm Genome (2014) 0.79
The Role of the Transcriptional Response to DNA Replication Stress. Genes (Basel) (2017) 0.79
Characterization of the role of Fhit in suppression of DNA damage. Adv Biol Regul (2012) 0.79
Fhit loss in lung preneoplasia: relation to DNA damage response checkpoint activation. Cancer Lett (2010) 0.79
Genome-wide reorganization of histone H2AX toward particular fragile sites on cell activation. Nucleic Acids Res (2013) 0.79
Nucleotide Pool Depletion Induces G-Quadruplex-Dependent Perturbation of Gene Expression. Cell Rep (2015) 0.78
Molecular biology: DNA fragility put into context. Nature (2011) 0.78
Remarkably Long-Tract Gene Conversion Induced by Fragile Site Instability in Saccharomyces cerevisiae. Genetics (2016) 0.76
Effects of Replication and Transcription on DNA Structure-Related Genetic Instability. Genes (Basel) (2017) 0.76
Evidence for chromosome fragility at the frataxin locus in Friedreich ataxia. Mutat Res (2015) 0.76
Tumor Suppressor Genes within Common Fragile Sites Are Active Players in the DNA Damage Response. PLoS Genet (2016) 0.75
Telomere dysfunction puts the brakes on oncogene-induced cancers. EMBO J (2012) 0.75
Rescue from replication stress during mitosis. Cell Cycle (2017) 0.75
To break or not to break - context matters. Mol Cell Oncol (2015) 0.75
Infection with retroviral vectors leads to perturbed DNA replication increasing vector integrations into fragile sites. Sci Rep (2013) 0.75
Perturbations in the Replication Program Contribute to Genomic Instability in Cancer. Int J Mol Sci (2017) 0.75
Fragile sites in cancer: more than meets the eye. Nat Rev Cancer (2017) 0.75
Monitoring Autophagy Immunohistochemically and Ultrastructurally during Human Head and Neck Carcinogenesis. Relationship with the DNA Damage Response Pathway. Int J Mol Sci (2017) 0.75
APOBEC3A and 3B activities render cancer cells susceptible to ATR inhibition. Cancer Res (2017) 0.75
Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology (2008) 8.10
Clinical impact of rapid in vitro susceptibility testing and bacterial identification. J Clin Microbiol (1994) 6.94
Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med (1998) 5.22
Fatal illness in general practice. J R Coll Gen Pract (1976) 3.64
EULAR recommendations for the management of Behçet disease. Ann Rheum Dis (2008) 3.37
Effect of infliximab on sight-threatening panuveitis in Behçet's disease. Lancet (2001) 2.95
Cell proteins bind to multiple sites within the 5' untranslated region of poliovirus RNA. Proc Natl Acad Sci U S A (1989) 2.65
The impact of urge urinary incontinence on quality of life: importance of patients' perspective and explanatory style. J Am Geriatr Soc (1998) 2.42
The adrenergic blocking activity of N-tert.-butylmethoxamine (butoxamine). J Pharmacol Exp Ther (1966) 2.25
Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum (2005) 2.05
Retracted Renaturation of denatured lambda repressor requires heat shock proteins. Cell (1990) 2.05
The human acid ceramidase gene (ASAH): structure, chromosomal location, mutation analysis, and expression. Genomics (1999) 2.04
Hairy cell leukemia: splenectomy after alpha 2b-interferon therapy. Blood (1991) 2.01
Imatinib for the treatment of refractory, diffuse systemic sclerosis. Rheumatology (Oxford) (2008) 1.83
Treatment of murine mucopolysaccharidosis type VII by syngeneic bone marrow transplantation in neonates. Lab Invest (1993) 1.81
A pilot study of endothelial dysfunction and aortic stiffness after interleukin-6 receptor inhibition in rheumatoid arthritis. Atherosclerosis (2011) 1.78
Identification of a promoter mapping within the reiterated sequences that flank the herpes simplex virus type 1 UL region. J Virol (1993) 1.77
SNP microarray-based 24 chromosome aneuploidy screening demonstrates that cleavage-stage FISH poorly predicts aneuploidy in embryos that develop to morphologically normal blastocysts. Mol Hum Reprod (2010) 1.76
Enzyme replacement therapy for murine mucopolysaccharidosis type VII. J Clin Invest (1994) 1.73
Evidence for a Niemann-pick C (NPC) gene family: identification and characterization of NPC1L1. Genomics (2000) 1.69
Neonatal gene transfer leads to widespread correction of pathology in a murine model of lysosomal storage disease. Proc Natl Acad Sci U S A (1999) 1.69
Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I. Mol Genet Metab (2004) 1.68
Renaturation kinetics of cDNA complementary to cytoplamic polyadenylated RNA from rainbow trout testis. Accessibility of transcribed genes to pancreatic DNase. Nucleic Acids Res (1977) 1.66
Oestrogen receptor beta (ERbeta) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour's dedifferentiation. Eur J Cancer (2003) 1.65
Increased life span and correction of metabolic defects in murine mucopolysaccharidosis type VII after syngeneic bone marrow transplantation. Blood (1991) 1.61
TNF-α antagonists beyond approved indications: stories of success and prospects for the future. QJM (2010) 1.57
Analysis of the herpes simplex virus type 1 promoter controlling the expression of UL38, a true late gene involved in capsid assembly. J Virol (1991) 1.54
An analysis of selective beta receptor blockade. Eur J Pharmacol (1969) 1.54
A murine model of mucopolysaccharidosis VII. Gross and microscopic findings in beta-glucuronidase-deficient mice. Am J Pathol (1990) 1.53
Dimethyl isopropylmethoxamine: a selective beta-receptor blocking agent. Br J Pharmacol Chemother (1966) 1.53
Glutamate levels and activity of the T cell voltage-gated potassium Kv1.3 channel in patients with systemic lupus erythematosus. Arthritis Rheum (2008) 1.51
Complex cytogenetic rearrangement of chromosome 8q in a case of Ambras syndrome. Am J Med Genet (2001) 1.48
Adrenal insufficiency as a complication of the acquired immunodeficiency syndrome. Ann Intern Med (1984) 1.45
Prenatal genetic carrier testing using triple disease screening. JAMA (1997) 1.43
Comparison of tomographic and planar radionuclide ventriculography in the assessment of regional left ventricular function in patients with left ventricular aneurysm before and after surgery. J Nucl Cardiol (1998) 1.42
Venous thromboembolism--prophylactic and therapeutic practice guideline. S Afr Med J (2009) 1.42
Small airways dysfunction in systemic sclerosis. A controlled study. Chest (1992) 1.39
Critical illness-related corticosteroid insufficiency in cardiogenic shock. Br J Anaesth (2013) 1.38
Involvement of E2F transcription factor family in cancer. Eur J Cancer (2005) 1.35
Partial purification of transcriptionally active nucleosomes from trout testis cells. Nucleic Acids Res (1978) 1.34
"High risk" HPV types are frequently detected in potentially malignant and malignant oral lesions, but not in normal oral mucosa. Mod Pathol (2000) 1.33
Murine mucopolysaccharidosis type VII: long term therapeutic effects of enzyme replacement and enzyme replacement followed by bone marrow transplantation. J Clin Invest (1997) 1.33
Enzyme replacement with recombinant beta-glucuronidase in murine mucopolysaccharidosis type VII: impact of therapy during the first six weeks of life on subsequent lysosomal storage, growth, and survival. Pediatr Res (1996) 1.33
Management of Behçet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behçet disease. Ann Rheum Dis (2008) 1.32
Enzyme replacement in murine mucopolysaccharidosis type VII: neuronal and glial response to beta-glucuronidase requires early initiation of enzyme replacement therapy. Pediatr Res (1999) 1.31
Advances in the biology of oral cancer. Oral Oncol (2007) 1.29
Myocardial infarction mediated by endothelin receptor signaling in hypercholesterolemic mice. Proc Natl Acad Sci U S A (1999) 1.28
Retinal toxicity in long term hydroxychloroquine treatment. Ann Rheum Dis (1996) 1.27
The actions of selective beta-receptor antagonists on the guinea pig trachea. Eur J Pharmacol (1970) 1.25
Intracranial injection of recombinant adeno-associated virus improves cognitive function in a murine model of mucopolysaccharidosis type VII. Mol Ther (2001) 1.24
Biodistribution, kinetics, and efficacy of highly phosphorylated and non-phosphorylated beta-glucuronidase in the murine model of mucopolysaccharidosis VII. J Biol Chem (2001) 1.23
Enzyme replacement with recombinant beta-glucuronidase in the newborn mucopolysaccharidosis type VII mouse. Pediatr Res (1993) 1.23
Protecting children from lead poisoning and building healthy communities. Am J Public Health (1999) 1.23
MRI in Lhermitte-Duclos disease. Neurology (1997) 1.23
Lack of involvement of nucleotide excision repair gene polymorphisms in colorectal cancer. Br J Cancer (2003) 1.23
Fidelity of chromatin transcription in vitro. Biochemistry (1976) 1.22
Factors related to the progression of myopia in Singaporean children. Optom Vis Sci (2000) 1.20
Enzyme replacement therapy for murine mucopolysaccharidosis type VII leads to improvements in behavior and auditory function. J Clin Invest (1998) 1.20
β-Catenin activation synergizes with PTEN loss to cause bladder cancer formation. Oncogene (2010) 1.20
Cardiovascular and bronchomotor responses to selective beta adrenergic receptor agonists in the anesthetized dog. J Pharmacol Exp Ther (1974) 1.19
Ras mutation cooperates with β-catenin activation to drive bladder tumourigenesis. Cell Death Dis (2011) 1.15
Activation of the JNK-AP-1 signal transduction pathway is associated with pathogenesis and progression of human osteosarcomas. Bone (2003) 1.14
Oncogenic driver mutations in patients with non-small-cell lung cancer at various clinical stages. Ann Oncol (2012) 1.13
Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease. Ann Intern Med (2004) 1.13
The value of vaginal cultures in general practice. J R Coll Gen Pract (1977) 1.13
B-cell kinase lyn deficiency in patients with systemic lupus erythematosus. J Investig Med (2001) 1.13
Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience. Oncology (2001) 1.12
Gender-dependent alterations in corticosteroid receptor status and spatial performance following 21 days of restraint stress. Neuroscience (2004) 1.11
C-MYC and IGF-II mRNA-binding protein (CRD-BP/IMP-1) in benign and malignant mesenchymal tumors. Int J Cancer (2001) 1.11
Dermoid, epidermoid, and teratomatous cysts of the tongue and the floor of the mouth. J Oral Surg (1974) 1.10
Serine phosphorylation of insulin receptor substrate-1: a novel target for the reversal of insulin resistance. Mol Endocrinol (2001) 1.10
Specific lipofuscin staining as a novel biomarker to detect replicative and stress-induced senescence. A method applicable in cryo-preserved and archival tissues. Aging (Albany NY) (2013) 1.09
Modes of epithelial cell death and repair in Sjögren's syndrome (SS). Clin Exp Immunol (1998) 1.08
Centrosome abnormalities are frequently observed in non-small-cell lung cancer and are associated with aneuploidy and cyclin E overexpression. J Pathol (2006) 1.06
Alterations of p16-pRb pathway and chromosome locus 9p21-22 in sporadic invasive breast carcinomas. Mol Med (1998) 1.06
Mucopolysaccharidosis VII: postmortem biochemical and pathological findings in a young adult with beta-glucuronidase deficiency. Mod Pathol (1994) 1.06
The DNA damage checkpoint precedes activation of ARF in response to escalating oncogenic stress during tumorigenesis. Cell Death Differ (2013) 1.06
Phosphorylation of Drosophila Jun by the MAP kinase rolled regulates photoreceptor differentiation. EMBO J (1996) 1.05
Selective beta adrenergic receptor blockade in the rat. J Pharmacol Exp Ther (1972) 1.05
Alterations of the p16-pRb pathway and the chromosome locus 9p21-22 in non-small-cell lung carcinomas: relationship with p53 and MDM2 protein expression. Am J Pathol (1998) 1.04
Effect of sex hormones on the response of mice to infection with Toxoplasma gondii. Br J Exp Pathol (1980) 1.04
A novel model of murine mucopolysaccharidosis type VII due to an intracisternal a particle element transposition into the beta-glucuronidase gene: clinical and pathologic findings. Pediatr Res (2001) 1.04
Oncogenic transformation of primary hamster cells by herpes simplex virus type 2 (hsv-2) and an hsv-2 temperature-sensitive mutant. Int J Cancer (1975) 1.03
The role of religion and ethnicity in the help seeking of family caregivers of elders with Alzheimer's disease and related disorders. J Cross Cult Gerontol (1999) 1.03
Clinical response to persistent, low-level beta-glucuronidase expression in the murine model of mucopolysaccharidosis type VII. J Inherit Metab Dis (2007) 1.03
Expression of the 27-kDa heat shock protein (HSP27) in gastric carcinomas and adjacent normal, metaplastic, and dysplastic gastric mucosa, and its prognostic significance. J Cancer Res Clin Oncol (2002) 1.03
Assessment of mycobacterial, propionibacterial, and human herpesvirus 8 DNA in tissues of greek patients with sarcoidosis. J Clin Microbiol (2002) 1.03
A histological and immunohistochemical study of the changes induced in the brains of white mice by infection with Toxoplasma gondii. Br J Exp Pathol (1984) 1.03
Characterization of Mycobacterium tuberculosis complex isolates from Greek patients with sarcoidosis by Spoligotyping. J Clin Microbiol (2005) 1.02
Long-lasting effects of stress on glucocorticoid receptor gene expression in the rat brain. Neuroendocrinology (1999) 1.02